

## Four simple steps to submit your referral.

1 PATIENT INFORM	<b>NATION</b>	■ New patien	t 🛘 Current patient
Patient's first name			
Last name			Middle initial
Date of birth	☐ Male ☐ Female	Last 4 digits o	fssn
Street address			Apt #
City			
Parent/guardian (if applicable)			
Cell phone			
Other phone			
E-mail address			
Patient's primary language: 🖵 Eng	glish 🖵 Other		
If other, please specify			
Please attach copies of front and ba	ick of patient's insuran	ice cards or comp	lete information below.
Insurance company			
Insurance companyPhone			
Phone			
PhoneInsured's name			
Phone Insured's name Insured's employer			
Phone			
Phone			
Phone Insured's name Insured's employer Relationship to patient			
Phone	yes, carrier		

2 PRESCRIE	BER INFORM	ΛΑΤΙΟΝ	All fields must be completed to expedite prescription fulfillment
Date	Time	Date i	medication needed:
Prescriber's first nam	e	Las	st name
Prescriber's title			
If NP or PA, under dir	ection of Dr		
Office contact and ti	tle		
Office contact e-mai	l		
Office/clinic/institut	ion name		
Clinic/hospital affilia	tion		
Street address			Suite #
City		State	Zip
Phone		Fax	
			nse #
Deliver product to:			
Clinic location			
$\geq$			
<b>3</b> CLINICAL	. INFORMA	TION	
Primary ICD-10 code:	■ E87.1 Hypo-osm	olality and hypo	onatremia
-	□ E22.2 Syndrome	of inappropriat	e secretion of antidiuretic hormone

☐ Other		
Secondary diagnoses:		
□ NYHA CHF class	D <i>l</i>	M □CKD □ASCVD
Relevant PMH		
Patient weight (kg)	Date o	f weight
☐ NKDA ☐ Known drug allergies _		
Concomitant medications		
Most recent hospitalization:		
Baseline serum sodium		(attach most recent labs to referral
Baseline urine osmolality		
Inpatient therapy start date		
Hospital discharge date		
Prior hyponatremia therapy:		
☐ Fluid restriction	L/day Sto	op date
☐ Vasopressin receptor antagonist	☐ Demeclocycline	□ 3% saline
□Other	ĺ	Stop date

Medication	Strength/Formulation	Directions	Quantity/Refills
□ Samsca® (tolvaptan)	☐ 15 mg tablets☐ 30 mg tablets	Titration: Initiation and re-initiation of therapy should occur in the hospital to evaluate therapeutic response and prevent osmotic demylenation from over-correction of hyponatremia.   Maintenance dose: Takemg by mouth once daily.	Dispense:  No more than 30 days supply*  Refills  *Note: Do not administer Samsca for more than 30 days to minimize the risk of liver injury.
□ tolvaptan	☐ 15 mg tablets☐ 30 mg tablets	Titration: Initiation and re-initiation of therapy should occur in the hospital to evaluate therapeutic response and prevent osmotic demylenation from over-correction of hyponatremia.  Maintenance dose: Take mg by mouth once daily.	Dispense:  No more than 30 days supply*  Refills  *Note: Do not administer Samsca for more than 30 days to minimize the risk of liver injury.

By signing below, I certify that the above therapy is medically necessary. I also authorize Accredo to initiate any de minimus authorization processes from applicable health plans, if needed, including the submission of any necessary forms to such health plans, to the extent not prohibited.

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. No STAMPS) PHYSICIAN SIGNATURE REQUIRED

Date Substitution allowed Date Dispense as written

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber

## Please fax completed form to 877.251.9381.

To reach your team, call toll-free 855.891.7977.

You can now monitor shipments and chat online if you have questions.

Go to MyAccredoPatients.com to log in or get started.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.